LSTA
- Lisata Therapeutics, Inc.
()
Overview
Company Summary
Lisata Therapeutics, Inc. (LSTA) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company specializes in the area of immuno-oncology, which involves harnessing the body's immune system to target and destroy cancer cells.
LSTA is primarily involved in the research and development of novel immunotherapies that aim to enhance the body's natural immune response against cancer. They use cutting-edge scientific techniques and technologies to identify potential targets that play a role in tumor growth and develop therapeutic interventions to counteract them.
The company's flagship product is a proprietary immunotherapy platform that utilizes genetically engineered T cells to specifically target tumor cells. These T cells are manipulated to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) that recognize and bind to cancer-specific antigens, triggering an immune response against the tumor cells. This approach holds the promise of highly targeted and personalized cancer treatments.
LSTA conducts preclinical and clinical research to evaluate the safety and efficacy of their therapeutic candidates. They work closely with research institutions, clinical collaborators, and regulatory authorities to ensure that their candidates meet the necessary standards and guidelines for approval.
In addition to their therapeutic pipeline, Lisata Therapeutics may also engage in collaborations and partnerships with other pharmaceutical companies, academic institutions, or research organizations to further advance their research and development efforts.
Overall, Lisata Therapeutics, Inc. is dedicated to advancing the field of cancer immunotherapy by developing innovative and effective treatments to improve patient outcomes and combat this devastating disease.